TildrakizumabILUMYA

7.1 The PBAC recommended the listing of tildrakizumab (TIL) 200 mg (100 mg/mL injection, 2 x 1 mL syringe) for the treatment of severe chronic plaque psoriasis for continuing treatment only. The PBAC considered that TIL 200 mg was non-inferior compared to TIL 100 mg in terms of efficacy and safety.PSD · Mar 2026

7.2 The PBAC considered that the nominated comparator, TIL 100 mg, was reasonable.PSD · Mar 2026

6.26 The submission presented a cost minimisation approach to the economic evaluation, calculated over a 2-year time horizon. The only costs included in the evaluation were the drug costs. The assumptions and components of the evaluation are shown in Table 11. 10 OFFICIALPSD · Mar 2026

OFFICIAL Public Summary Document - March 2026 PBAC Meeting Table 11: Key assumptions and components of the economic evaluation Component Claim or assumption Therapeutic claim: effectiveness The clinical evaluation showed that TIL 200 mg Q12W is non-inferior to TIL 100 mg Q12W in terms of efficacy.PSD · Mar 2026

6.22 The submission described TIL 200 mg as non-inferior in terms of effectiveness compared to TIL 100 mg. No evidence was presented that demonstrated that an increase of the continuing treatment dose from TIL 100 mg to TIL 200 mg is associated with improved outcomes.PSD · Mar 2026

6.23 The submission described TIL 200 mg as non-inferior in terms of safety compared to TIL 100 mg.PSD · Mar 2026